Terminated/Withdrawn
Sponsor ID
20080733
AMG 745 in Subjects with Age-associated Muscle Loss
Study Details
Randomized, Double-blind, Placebo-controlled Dose Ranging Study to Evaluate the Safety and Efficacy of AMG 745 in Age-associated Muscle Loss
Protocol Summary
Primary Outcome Measures
To evaluate the effect of AMG 745 weekly IV doses of 0.3 mg/kg, 1.0 mg/kg, or 3.0 mg/kg, compared with weekly IV placebo on thigh muscle CSA in subjects ≥ 65 yrs old with limited exercise tolerance and functional limitations
Timeframe: 12 Weeks
Secondary Outcome Measures
To evaluate the effect of treatment with AMG 745 on muscle strength (hand grip strength) and function (gait speed, 10-step stair climb power, chair stand and 6 minute walk distance) and to evaluate the PK of AMG 745 following multiple IV administrations
Timeframe: 12 Weeks
Locations
No locations found.